

with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug.

69. An isolated B7-2 fusion protein.

#### REMARKS

Claims 1-27 and 29-64 have been canceled without prejudice. Claims 65-69 have been added. Claim 28 has been amended. Accordingly, claims 28 and 65-69 are currently pending in the application.


The above amendments and cancellation of claims were made solely to expedite prosecution of the application and should not be construed as an acquiescence to any rejection. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

Support for the above claim amendments can be found through out the specification and claims as originally filed. Support for new claims 65-69 can also be found in the specification and/or claims as filed. Specifically, support for "a soluble form of B7-2" can be found at least at page 3, line. 8. Support for "an antibody that recognizes B7-2" can be found at least at page beginning at page 33. Support for "an agent that blocks the interaction of B7-1 with its natural ligand" can be found at least at page 40, lines 30-35. Support for "antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug" can be found at least at page 41, lines 9-11. No new matter has been added.

SUMMARY

If a telephone conversation with Applicants' Agent would expedite the prosecution of the above-identified application, the examiner is urged to call Applicants' Agent at (617) 227-7400.

Respectfully submitted,



Megan E. Williams  
Registration No. 43,270  
Agent for Applicants

LAHIVE & COCKFIELD, LLP  
60 State Street  
Boston, MA 02109  
(617) 227-5941

Dated: October 22, 1999

0942516 102299